Here are the 8-K filings from BlossomHill Therapeutics, Inc. (BLSM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow BLSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLSM filings page.
BlossomHill Therapeutics, Inc. (BLSM) reported second quarter 2026 results, highlighting higher operating spending as it advances its oncology pipeline and prepares for later-stage trials. Research and development expenses were $21.4 million and general and administrative expenses were $3.3 million, both above the prior-year quarter, driving a quarterly net loss of $23.8 million, or $(8.75) per share.
Cash and cash equivalents were $95.4 million as of June 30, 2026, and the company subsequently completed an upsized initial public offering of 10,516,240 shares for $168.3 million in gross proceeds. BlossomHill believes this cash, together with IPO proceeds, will fund operations into the second quarter of 2028.
Operationally, BH-30643, the lead OMNI-EGFR™ inhibitor for EGFR-mutant NSCLC, received FDA Fast Track designation and is in a global Phase 1/2 trial. BH-30236, a CLK inhibitor for R/R AML and HR-MDS, holds orphan drug designation, and BH-501284, a preclinical pan-KRAS inhibitor, showed encouraging preclinical data, underscoring a broad, oncology-focused small-molecule pipeline.
BlossomHill Therapeutics, Inc. (BLSM) reported updated clinical data from its ongoing global Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer patients with secondary EGFR resistance mutations such as EGFR C797S. In patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, BH-30643 showed a 45% objective response rate (18/40) and an 88% disease control rate (35/40) as of the May 12, 2026 data cutoff, with efficacy follow-up through August 10, 2026. At efficacy follow-up, 63% of patients (25/40) remained on treatment, with a median follow-up of 6.9 months. The company states that BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events and notes that this presentation follows receipt of FDA Fast Track designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC. BlossomHill plans to advance BH-30643 into a Phase 2 trial in patients with C797S-positive NSCLC in 2027.